Format

Send to

Choose Destination
See comment in PubMed Commons below
Int J Cardiol. 2014 Jul 1;174(3):471-83. doi: 10.1016/j.ijcard.2014.04.179. Epub 2014 Apr 26.

Pharmacology, benefits, unaddressed questions, and pragmatic issues of the newer oral anticoagulants for stroke prophylaxis in non-valvular atrial fibrillation and proposal of a management algorithm.

Author information

1
Department of Internal Medicine, Division of Cardiology, University of North Texas Health Science Center, Fort Worth, TX, United States. Electronic address: Salvatore.Rosanio@unthsc.edu.
2
Department of Internal Medicine, Division of Cardiology, University of North Texas Health Science Center, Fort Worth, TX, United States.
3
Cardio-Respiratory Department, La Sapienza University, Rome, Italy.

Abstract

This systematic review aims to provide an update on pharmacology, efficacy and safety of the newer oral direct thrombin and factor Xa inhibitors, which have emerged for the first time in ~60 years as cogent alternatives to warfarin for stroke prophylaxis in non-valvular atrial fibrillation. We also discuss on four of the most common clinical scenarios with several unsolved questions and areas of uncertainty that may play a role in physicians' reluctance to prescribe the newer oral anticoagulants such as 1) patients with renal failure; 2) the elderly; 3) patients presenting with atrial fibrillation and acute coronary syndromes and/or undergoing coronary stenting; and 4) patients planning to receive AF ablation with the use of pulmonary vein isolation. New aspects presented in current guidelines are covered and we also propose an evidence-based anticoagulation management algorithm.

KEYWORDS:

Apixaban; Atrial fibrillation; Dabigatran; Edoxaban; Rivaroxaban; Stroke

PMID:
24814537
DOI:
10.1016/j.ijcard.2014.04.179
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center